Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.

Specific targeting of tumors by combined delivery of drugs and of imaging agents represents an attractive strategy for treatment of cancer. The aim of the present study was to investigate whether neural cell adhesion molecule (NCAM)-targeted liposomes may enhance drug delivery and allow magnetic resonance imaging (MRI) in a severe combined immunodeficient mouse model of NCAM-positive Kaposi's sarcoma. NCAM-binding peptide-coated liposomes loaded with both doxorubicin and a lipophilic gadolinium (Gd) derivative were generated. NCAM-targeted liposomes induced an enhanced in vitro doxorubicin internalization within Kaposi's cells as detected by MRI with respect to untargeted polyethylene glycol liposomes. Internalization resulted in enhanced apoptosis. In vivo weekly administration of NCAM-targeted liposomes containing 5 mg/kg doxorubicin for 4 consecutive weeks induced a significant reduction of tumor mass and vascularization and enhanced cell necrosis and apoptosis with respect to untargeted liposomes. These effects were associated with an enhanced concentration of doxorubicin within the tumor and a reduced systemic toxicity of doxorubicin. By electron microscopy, NCAM-targeted liposomes were detected mainly within tumor cells whereas the untargeted liposomes were mainly accumulated in the extracellular space. Gd-labeled liposomes allowed the MRI visualization of drug delivery in the tumor region. The intensity of MRI signal was partially hampered by the "quenching" of the attainable relaxation enhancement on endosomal entrapment of the Gd-labeled liposomes. In conclusion, targeting NCAM may be a suitable strategy for specific drug delivery and imaging by liposomes in NCAM-expressing tumors. Moreover, treatment with NCAM-targeted liposomes showed enhanced therapeutic effect and reduced toxicity with respect to untargeted liposomes.

[1]  Mathilde H. Lerche,et al.  Identification of a neuritogenic ligand of the neural cell adhesion molecule using a combinatorial library of synthetic peptides , 1999, Nature Biotechnology.

[2]  J. Dufour,et al.  Effects on hepatocellular carcinoma of doxorubicin-loaded immunoliposomes designed to target the VEGFR-2 , 2007, Journal of drug targeting.

[3]  G. Keating,et al.  Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. , 2002, Drugs.

[4]  M. Brizzi,et al.  HIV-1-Tat Protein Activates Phosphatidylinositol 3-Kinase/ AKT-dependent Survival Pathways in Kaposi's Sarcoma Cells* , 2002, The Journal of Biological Chemistry.

[5]  Z. Bhujwalla,et al.  Image-Guided Enzyme/Prodrug Cancer Therapy , 2008, Clinical Cancer Research.

[6]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[7]  G. Koning,et al.  Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. , 2007, Anti-cancer agents in medicinal chemistry.

[8]  P. Anelli,et al.  Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[9]  L. Tei,et al.  Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. , 2006, Cancer research.

[10]  Sylvia Wagner,et al.  Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. , 2008, Bioconjugate chemistry.

[11]  F. Walsh,et al.  Neural cell adhesion molecules of the immunoglobulin superfamily: role in axon growth and guidance. , 1997, Annual review of cell and developmental biology.

[12]  L. Tei,et al.  Neural-cell adhesion molecule (NCAM) expression by immature and tumor-derived endothelial cells favors cell organization into capillary-like structures. , 2006, Experimental cell research.

[13]  A. Gabizon,et al.  Polyethylene Glycol-Coated (Pegylated) Liposomal Doxorubicin , 2012, Drugs.

[14]  S. Aime,et al.  Efficient Cellular Labeling by CD44 Receptor‐Mediated Uptake of Cationic Liposomes Functionalized with Hyaluronic Acid and Loaded with MRI Contrast Agents , 2008, ChemMedChem.

[15]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[16]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[17]  M. Bally,et al.  The liposomal formulation of doxorubicin. , 2005, Methods in enzymology.

[18]  G. Camussi,et al.  Altered angiogenesis and survival in human tumor‐derived endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  M Sculpher,et al.  Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model. , 2006, Health technology assessment.

[20]  Hui Zhao,et al.  RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer , 2009, Journal of drug targeting.

[21]  S. Nakamura,et al.  Kaposi's sarcoma cells: long-term culture with growth factor from retrovirus-infected CD4+ T cells. , 1988, Science.

[22]  R. Mitsuyasu.  Update on the pathogenesis and treatment of Kaposi sarcoma , 2000, Current opinion in oncology.

[23]  A. Gabizon,et al.  Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. , 1997, Drugs.

[24]  W. Scheithauer,et al.  Phase II trial of pegylated liposomal doxorubicin (Caelyx™) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer , 2007, Acta oncologica.

[25]  S. Palmer,et al.  Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. , 2006, Health Technology Assessment.

[26]  F. Berthold,et al.  Targeting the neural cell adhesion molecule in cancer. , 2007, Cancer letters.

[27]  M. Gonda,et al.  Expression and modulation of surface antigens in cultured rat glomerular visceral epithelial cells. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  E. Frenkel,et al.  Nanoparticles for drug delivery in cancer treatment. , 2008, Urologic oncology.

[29]  Khaled Greish,et al.  Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.

[30]  J. Dufour,et al.  Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. , 2008, Journal of hepatology.

[31]  G. Bendas,et al.  VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. , 2008, Biochimica et biophysica acta.

[32]  R. Schwendener.  Liposomes in biology and medicine. , 2007, Advances in experimental medicine and biology.

[33]  Enzo Terreno,et al.  Effect of the intracellular localization of a Gd‐based imaging probe on the relaxation enhancement of water protons , 2006, Magnetic resonance in medicine.

[34]  P. Volberding,et al.  Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.

[35]  Chien-Hsun Wu,et al.  A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung Cancer , 2009, PloS one.

[36]  M Greaves,et al.  Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. , 2006, Health technology assessment.

[37]  A. Sood,et al.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.

[38]  F. Szoka,et al.  Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. , 1979, Biochimica et biophysica acta.

[39]  T. Allen.  Long-circulating (sterically stabilized) liposomes for targeted drug delivery. , 1994, Trends in pharmacological sciences.

[40]  J. Wolff,et al.  Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors , 2007, Journal of Neuro-Oncology.

[41]  D. Tzemach,et al.  Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  Gert Storm,et al.  Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.

[43]  R. Muller,et al.  Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity. , 1999, Magnetic resonance imaging.

[44]  F. Martin,et al.  Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. , 2004, Seminars in oncology.

[45]  R. Schiffelers,et al.  Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. , 2008, International journal of pharmaceutics.

[46]  S. Rabbani,et al.  Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects , 2007, Anti-cancer drugs.

[47]  V. Berezin,et al.  A Synthetic Peptide Ligand of Neural Cell Adhesion Molecule (NCAM), C3d, Promotes Neuritogenesis and Synaptogenesis and Modulates Presynaptic Function in Primary Cultures of Rat Hippocampal Neurons* , 2003, The Journal of Biological Chemistry.

[48]  V. Berezin,et al.  The neural cell adhesion molecule in synaptic plasticity and ageing , 2000, International Journal of Developmental Neuroscience.

[49]  A. Albini,et al.  The β‐core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma‐derived cells and a new immortalized Kaposi's sarcoma cell line , 1997, AIDS.

[50]  D. Osoba,et al.  Use of liposomal anthracyclines in Kaposi's sarcoma. , 2004, Seminars in oncology.